Comparison Overview

bioMérieux

VS

Gilead Sciences

bioMérieux

100, Allée Louis Pasteur, None, Marcy-l'Étoile, Auvergne-Rhône-Alpes, FR, 69280
Last Update: 2025-11-25
Between 750 and 799

A family-owned company, bioMérieux has grown to become a world leader in the field of in vitro diagnostics. Our entrepreneurial adventure, begun over a century ago, is driven by an unrelenting commitment to improve public health worldwide. Since 1963, we've been paving the way in the field of in vitro diagnostics and have contributed greatly to improving public health and making the world a healthier place. The solutions that our teams imagine, develop and manufacture are key to enable healthcare professionals and industry players to make confident decisions to improve patient outcome and ensure consumer safety.

NAICS: 541714
NAICS Definition: Research and Development in Biotechnology (except Nanobiotechnology)
Employees: 12,724
Subsidiaries: 6
12-month incidents
0
Known data breaches
0
Attack type number
1

Gilead Sciences

333 Lakeside Drive, Foster City, CA, US, 94404
Last Update: 2025-11-25
Between 800 and 849

At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines

NAICS: 541714
NAICS Definition: Research and Development in Biotechnology (except Nanobiotechnology)
Employees: 14,615
Subsidiaries: 10
12-month incidents
1
Known data breaches
1
Attack type number
2

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/biomerieux.jpeg
bioMérieux
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/gilead-sciences.jpeg
Gilead Sciences
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
bioMérieux
100%
Compliance Rate
0/4 Standards Verified
Gilead Sciences
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Biotechnology Research Industry Average (This Year)

No incidents recorded for bioMérieux in 2025.

Incidents vs Biotechnology Research Industry Average (This Year)

Gilead Sciences has 25.0% more incidents than the average of same-industry companies with at least one recorded incident.

Incident History — bioMérieux (X = Date, Y = Severity)

bioMérieux cyber incidents detection timeline including parent company and subsidiaries

Incident History — Gilead Sciences (X = Date, Y = Severity)

Gilead Sciences cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/biomerieux.jpeg
bioMérieux
Incidents

Date Detected: 6/2023
Type:Vulnerability
Attack Vector: Unauthorized Access
Blog: Blog
https://images.rankiteo.com/companyimages/gilead-sciences.jpeg
Gilead Sciences
Incidents

Date Detected: 2/2025
Type:Breach
Attack Vector: Human Error (Mailing Error)
Blog: Blog

Date Detected: 05/2020
Type:Cyber Attack
Attack Vector: Phishing, Server Compromise
Blog: Blog

FAQ

Gilead Sciences company demonstrates a stronger AI Cybersecurity Score compared to bioMérieux company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Gilead Sciences company has faced a higher number of disclosed cyber incidents historically compared to bioMérieux company.

In the current year, Gilead Sciences company has reported more cyber incidents than bioMérieux company.

Neither Gilead Sciences company nor bioMérieux company has reported experiencing a ransomware attack publicly.

Gilead Sciences company has disclosed at least one data breach, while bioMérieux company has not reported such incidents publicly.

Gilead Sciences company has reported targeted cyberattacks, while bioMérieux company has not reported such incidents publicly.

bioMérieux company has disclosed at least one vulnerability, while Gilead Sciences company has not reported such incidents publicly.

Neither bioMérieux nor Gilead Sciences holds any compliance certifications.

Neither company holds any compliance certifications.

Gilead Sciences company has more subsidiaries worldwide compared to bioMérieux company.

Gilead Sciences company employs more people globally than bioMérieux company, reflecting its scale as a Biotechnology Research.

Neither bioMérieux nor Gilead Sciences holds SOC 2 Type 1 certification.

Neither bioMérieux nor Gilead Sciences holds SOC 2 Type 2 certification.

Neither bioMérieux nor Gilead Sciences holds ISO 27001 certification.

Neither bioMérieux nor Gilead Sciences holds PCI DSS certification.

Neither bioMérieux nor Gilead Sciences holds HIPAA certification.

Neither bioMérieux nor Gilead Sciences holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

Angular is a development platform for building mobile and desktop web applications using TypeScript/JavaScript and other languages. Prior to versions 19.2.16, 20.3.14, and 21.0.1, there is a XSRF token leakage via protocol-relative URLs in angular HTTP clients. The vulnerability is a Credential Leak by App Logic that leads to the unauthorized disclosure of the Cross-Site Request Forgery (XSRF) token to an attacker-controlled domain. Angular's HttpClient has a built-in XSRF protection mechanism that works by checking if a request URL starts with a protocol (http:// or https://) to determine if it is cross-origin. If the URL starts with protocol-relative URL (//), it is incorrectly treated as a same-origin request, and the XSRF token is automatically added to the X-XSRF-TOKEN header. This issue has been patched in versions 19.2.16, 20.3.14, and 21.0.1. A workaround for this issue involves avoiding using protocol-relative URLs (URLs starting with //) in HttpClient requests. All backend communication URLs should be hardcoded as relative paths (starting with a single /) or fully qualified, trusted absolute URLs.

Risk Information
cvss4
Base: 7.7
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:N/SC:H/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Forge (also called `node-forge`) is a native implementation of Transport Layer Security in JavaScript. An Uncontrolled Recursion vulnerability in node-forge versions 1.3.1 and below enables remote, unauthenticated attackers to craft deep ASN.1 structures that trigger unbounded recursive parsing. This leads to a Denial-of-Service (DoS) via stack exhaustion when parsing untrusted DER inputs. This issue has been patched in version 1.3.2.

Risk Information
cvss4
Base: 8.7
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Forge (also called `node-forge`) is a native implementation of Transport Layer Security in JavaScript. An Integer Overflow vulnerability in node-forge versions 1.3.1 and below enables remote, unauthenticated attackers to craft ASN.1 structures containing OIDs with oversized arcs. These arcs may be decoded as smaller, trusted OIDs due to 32-bit bitwise truncation, enabling the bypass of downstream OID-based security decisions. This issue has been patched in version 1.3.2.

Risk Information
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Suricata is a network IDS, IPS and NSM engine developed by the OISF (Open Information Security Foundation) and the Suricata community. Prior to versions 7.0.13 and 8.0.2, working with large buffers in Lua scripts can lead to a stack overflow. Users of Lua rules and output scripts may be affected when working with large buffers. This includes a rule passing a large buffer to a Lua script. This issue has been patched in versions 7.0.13 and 8.0.2. A workaround for this issue involves disabling Lua rules and output scripts, or making sure limits, such as stream.depth.reassembly and HTTP response body limits (response-body-limit), are set to less than half the stack size.

Risk Information
cvss3
Base: 7.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H
Description

Suricata is a network IDS, IPS and NSM engine developed by the OISF (Open Information Security Foundation) and the Suricata community. In versions from 8.0.0 to before 8.0.2, a NULL dereference can occur when the entropy keyword is used in conjunction with base64_data. This issue has been patched in version 8.0.2. A workaround involves disabling rules that use entropy in conjunction with base64_data.

Risk Information
cvss3
Base: 7.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H